Synonyms: ARS1620 | example 227 [US9840516B2]
Compound class:
Synthetic organic
Comment: ARS-1620 was designed to target mutated KRASG12C in cancer [1]. It binds covalently to GDP-bound KRASG12C and traps it in the inactive conformation. Structurally ARS-1620 is the S-atropisomer. It represents a pharmacological tool that is suitable for use in in vitro and in vivo experiments to further explore KRAS dependency in KRAS mutant cancers. The chemical structure is claimed in Araxes Pharma's patent US9840516B2
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
ARS-1620 inhibits RAS signalling in vitro with an IC50 of 120 nM, whereas the R-atropisomer is inactive in the same assays [1]. It is effictive as a single agent in cell line- and patient-derived mouse xenograft models of KRASG12C-driven cancer . |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|